Publications (227) HERNÁN CORTÉS-FUNES CASTRO publications

filter_list

2023

  1. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

    Journal of Clinical Oncology, Vol. 41, Núm. 33, pp. 5080-5089

2022

  1. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies

    Therapeutic Advances in Medical Oncology, Vol. 14

2017

  1. Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin

    Molecular Cancer, Vol. 16, Núm. 1

2015

  1. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study

    Anticancer research, Vol. 35, Núm. 12, pp. 6941-6950

  2. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

    European Journal of Cancer, Vol. 51, Núm. 12, pp. 1481-1489

  3. Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer

    Tumor Biology, Vol. 36, Núm. 2, pp. 1199-1206

  4. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer

    Journal of Cancer Research and Clinical Oncology, Vol. 141, Núm. 1, pp. 43-53

  5. Risk factors associated with Clostridium difficile infection in adult oncology patients

    Supportive Care in Cancer, Vol. 23, Núm. 6, pp. 1569-1577

2014

  1. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial

    Breast, Vol. 23, Núm. 5, pp. 656-662

  2. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer

    Breast, Vol. 23, Núm. 3, pp. 201-208

2013

  1. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: Implications for outcomes and histologic classification

    Carcinogenesis, Vol. 34, Núm. 5, pp. 1031-1038

  2. Guidelines for the management of breakthrough pain in patients with cancer

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, Núm. SUPPL.1

  3. Phase i study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

    Cancer Chemotherapy and Pharmacology, Vol. 72, Núm. 1, pp. 75-83

  4. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer

    Anti-Cancer Drugs, Vol. 24, Núm. 8, pp. 769-780

  5. Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 467-471

2012

  1. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 606-612

  2. Behaviour of breast cancer molecular subtypes through tumour progression

    Clinical and Translational Oncology, Vol. 14, Núm. 6, pp. 481-485

  3. Biological markers of cisplatin resistance in advanced testicular germ cell tumours

    Clinical and Translational Oncology, Vol. 14, Núm. 6, pp. 452-457

  4. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

    British Journal of Cancer, Vol. 106, Núm. 8, pp. 1379-1385

  5. First-line bevacizumab-containing therapy for triple-negative breast cancer: Analysis of 585 patients treated in the ATHENA study

    Oncology, Vol. 82, Núm. 4, pp. 218-227